No annual revenue total was found in INTENSITY THERAPEUTICS, INC.'s SEC filings.
Intensity Therapeutics, Inc. (INTS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Sep 30, 2026 it held $8.5 million in cash and investments and $87,000 in total debt.
Revenue
—
Net income (TTM)
$-12.04M
-2.6% vs year-ago TTM
Operating cash flow (TTM)
$-9.07M
+4.6% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-4.45
-440.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.54M
-83.3% vs prior year
Net cash
$8.41M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1567264
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Operating income | -$12.0M | -$16.6M | -$8.3M |
| Net income | -$11.6M | -$16.3M | -$10.5M |
| Diluted EPS | -$8.56 | -$29.24 | -$1.38 |
| Operating cash flow | -$9.2M | -$15.2M | -$7.2M |
| Total assets | $14.1M | $4.8M | $17.3M |
| Total liabilities | $2.2M | $1.9M | $4.1M |
| Stockholders' equity | $11.9M | $2.9M | $13.2M |
| Cash and investments | $11.9M | $2.6M | $8.6M |
| Total debt | $110,000 | $138,000 | $158,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 246 Intensity Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.